Mary Eapen, MRCPI, MS, MBBS

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MRCPI - Gen Med Royal College of Phy of Ireland
MS -Master of Science
MBBS - Doctor of Medicine

Biography

Dr. Eapen received her MBBS from Ahmadu Bello University, Zaria, Nigeria, in 1987. She completed a pediatric residency in 1997. In 2000, Dr. Eapen completed a fellowship in hematology/oncology/blood and bone marrow transplant and a MS in Clinical Research at the University of Minnesota, Minneapolis, Minnesota.

Research Interests

Mary Eapen, MD, MS, is Professor at the Medical College of Wisconsin and Senior Scientific Director - Research, Center for International Blood and Marrow Transplant Research. Her research focuses on the use of graft sources other than bone marrow for allogeneic hematopoietic cell transplantation for acute leukemia and marrow failure disorders.

Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.

(Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, Horowitz MM, Kamani N, Walters MC, Shenoy S.) Am J Hematol. 2024 Apr;99(4):785-788 PMID: 38343182 PMCID: PMC10947844 SCOPUS ID: 2-s2.0-85185139592 02/12/2024
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479] (Best Practice & Research Clinical Haematology (2023) 36(3), (S1521692623000403), (10.1016/j.beha.2023.101479))

(Brazauskas R, Eapen M, Wang T.) Best Practice and Research: Clinical Haematology. March 2024;37(1) SCOPUS ID: 2-s2.0-85185562266 03/01/2024
Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States.

(Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD Jr, D'Souza A.) Bone Marrow Transplant. 2023 Dec;58(12):1400-1402 PMID: 37673983 SCOPUS ID: 2-s2.0-85170080925 09/07/2023
No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.

(Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano JA, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.) Bone Marrow Transplant. 2023 Dec;58(12):1390-1393 PMID: 37666957 SCOPUS ID: 2-s2.0-85169665242 09/05/2023
Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy.

(Nakamura R, Patel BA, Kim S, Wong FL, Armenian SH, Groarke EM, Keesler DA, Hebert KM, Heim M, Eapen M, Young NS.) Haematologica. 2023 Dec 01;108(12):3298-3307 PMID: 37259612 PMCID: PMC10690917 SCOPUS ID: 2-s2.0-85171560866 06/01/2023
Endpoint selection and evaluation in hematology studies.

(Brazauskas R, Eapen M, Wang T.) Best Pract Res Clin Haematol. 2023 Sep;36(3):101479 PMID: 37611997 PMCID: PMC10979628 SCOPUS ID: 2-s2.0-85161313534 08/24/2023
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.

(Geerlinks AV, Scull B, Krupski C, Fleischmann R, Pulsipher MA, Eapen M, Connelly JA, Bollard CM, Pai SY, Duncan CN, Kean LS, Baker KS, Burroughs LM, Andolina JR, Shenoy S, Roehrs P, Hanna R, Talano JA, Schultz KR, Stenger EO, Lin H, Zoref-Lorenz A, McClain KL, Jordan MB, Man TK, Allen CE, Marsh RA.) Blood Adv. 2023 Jul 25;7(14):3725-3734 PMID: 37042921 PMCID: PMC10368780 SCOPUS ID: 2-s2.0-85183633571 04/13/2023
Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.

(Ramsey SD, Bansal A, Li L, O'Donnell PV, Fuchs EJ, Brunstein CG, Eapen M, Thao V, Roth JA, Steuten LMG.) Transplant Cell Ther. 2023 Jul;29(7):464.e1-464.e8 PMID: 37120135 PMCID: PMC10353308 SCOPUS ID: 2-s2.0-85160025736 04/30/2023
Reply to R. Meisel.

(Eapen M, Brazaukas R.) J Clin Oncol. 2023 Jun 10;41(17):3273-3274 PMID: 37043706 PMCID: PMC10256417 SCOPUS ID: 2-s2.0-85163236843 04/13/2023
What causes aplastic anaemia?

(Gale RP, Hinterberger W, Young NS, Gennery AR, Dvorak CC, Hebert KM, Heim M, Broglie L, Eapen M.) Leukemia. 2023 Jun;37(6):1191-1193 PMID: 37106162 PMCID: PMC10353698 SCOPUS ID: 2-s2.0-85153963425 04/28/2023
Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors.

(Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Rotz SJ, Fraint E, Rangarajan HG, Auletta JJ, Sharma A, Kitko CL, Hashem H, Williams KM, Wirk B, Dvorak CC, Myers KC, Pulsipher MA, Warwick AB, Lalefar NR, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.) Transplant Cell Ther. 2023 Jun;29(6):380.e1-380.e9 PMID: 36990222 PMCID: PMC10247464 SCOPUS ID: 2-s2.0-85153799554 03/30/2023
Endpoint selection and evaluation in hematology studies

(Brazauskas R, Eapen M, Wang T.) Best Practice and Research: Clinical Haematology. September 2023;36(3) SCOPUS ID: 2-s2.0-85161313534 09/01/2023